title: Idiopathic systemic capillary leak syndrome: novel therapy for acute attacks.
authors.forename: Amy M
authors.initials: AM
authors.lastname: Dowden
authors.forename: Ornella J
authors.initials: OJ
authors.lastname: Rullo
authors.forename: Najib
authors.initials: N
authors.lastname: Aziz
authors.forename: Mary Beth
authors.initials: MB
authors.lastname: Fasano
authors.forename: Talal
authors.initials: T
authors.lastname: Chatila
authors.forename: Zuhair K
authors.initials: ZK
authors.lastname: Ballas
mesh_terms: D000208:Acute Disease; D000628:Aminophylline / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019559:Capillary Leak Syndrome / Q000188:drug therapy* / Q000276:immunology; D002199:Capillary Permeability / Q000187:drug effects; D002648:Child; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D013726:Terbutaline / Q000627:therapeutic use*; D013806:Theophylline / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D016207:Cytokines; D007155:Immunologic Factors; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D000628:Aminophylline; D000069285:Infliximab; D013806:Theophylline; D013726:Terbutaline